MajorSelective reversible acetylcholinesterase inhibitor×Acetylcholinesterase inhibitor with allosteric nicotinic modulation
Updated · Methodology
Mechanism
Galantamine is a selective, competitive and reversible inhibitor of acetylcholinesterase and also strengthens the intrinsic action of acetylcholine on nicotinic receptors (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Donepezil is also a specific and reversible inhibitor of acetylcholinesterase, the main cholinesterase in the brain (donepezil SmPC, AEMPS, section 5.1). Because of this mechanism, galantamine should not be given with other cholinomimetics, including donepezil (galantamine SmPC, AEMPS, section 4.5). The US galantamine label expects a synergistic effect with other cholinesterase inhibitors (galantamine label, US Food and Drug Administration, FDA, section 7.2). The documents describe no pharmacokinetic interaction for this pair. In the liver, the enzyme CYP3A4 and, to a lesser extent, CYP2D6 metabolise donepezil (donepezil SmPC, AEMPS, section 4.5). Galantamine has several elimination pathways and a low likelihood of clinically relevant pharmacokinetic interactions (galantamine SmPC, AEMPS, section 4.5).
Symptoms
The documents do not describe how this particular combination presents: galantamine and donepezil are not given together in the first place because they share a mechanism of action (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Through vagal effects, both drugs can slow the heart rate and cause heart block. QTc prolongation has been reported with both, and torsade de pointes with donepezil in post-marketing reports and with galantamine in overdose (galantamine and donepezil SmPCs, AEMPS, section 4.4). The overdose section of the galantamine SmPC shows what excess cholinergic action looks like: muscle weakness or fasciculations, severe nausea, vomiting, gastrointestinal cramps, salivation, lacrimation, urination, defecation, sweating, slow heart rate, low blood pressure, collapse and seizures. Increasing muscle weakness, together with tracheal hypersecretion and bronchospasm, can compromise the airway (galantamine SmPC, AEMPS, section 4.9).
Management
Avoid the combination. Galantamine should not be given with other cholinomimetics, and donepezil is named among them (galantamine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The donepezil SmPC says to avoid combining donepezil with other acetylcholinesterase inhibitors (donepezil SmPC, AEMPS, section 4.4). The contraindication sections of the Spanish and US prescribing information for both drugs do not list this pair. The documents give no interval for switching from one drug to the other. The half-life of donepezil is about 70 hours, and donepezil and its metabolites may persist in the body for more than 10 days (donepezil SmPC, AEMPS, section 5.2). Galantamine is started at 8 mg a day for 4 weeks (galantamine SmPC, AEMPS, section 4.2). If signs of cholinergic crisis appear, manage them as an overdose with general supportive measures. In severe cases, intravenous atropine can be used: the starting dose is 0.5–1.0 mg according to the galantamine SmPC and 1.0–2.0 mg according to the donepezil SmPC, with further doses based on clinical response (galantamine and donepezil SmPCs, AEMPS, section 4.9).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Galantamina, Reminyl 16 mg cápsulas duras de liberación prolongada (nº registro 66651), sección 4.5 (2026)– AEMPS, CIMA, nº registro 66651 (Reminyl 16 mg cápsulas duras de liberación prolongada, Essential Pharma), revisión 09/2026, secciones 4.2, 4.4, 4.5, 4.9 y 5.1
- AEMPS: Ficha técnica: Donepezilo, Aricept 10 mg comprimidos recubiertos con película (nº registro 61870), sección 4.4 (2024)– AEMPS, CIMA, nº registro 61870 (Aricept 10 mg comprimidos recubiertos con película, Eisai), revisión 09/2024, secciones 4.4, 4.5, 4.9, 5.1 y 5.2
- FDA: Aricept (donepezil hydrochloride) prescribing information (2021)– FDA, DailyMed setid 98e451e1-e4d7-4439-a675-c5457ba20975 (Eisai), versión 33, revisión 12/2021, secciones 4, 5.2 y 7.2
- FDA: Galantamine tablets (Upsher-Smith) prescribing information (2024)– FDA, DailyMed setid 10497273-d907-0514-e063-6294a90a1362 (Upsher-Smith Laboratories), versión 8, revisión 11/2024, secciones 4, 5.3 y 7.2